MBOT Microbot Medical Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883975 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-26.3%
ROA-24.8%
ROIC (approx.)-25.2%
Asset turnover—
Leverage & solvency
Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $72,000 | $241,000 | $105,000 | — | — | — | — | — |
| Cost of revenue | $1.09M | $884,000 | $103,000 | — | — | — | — | — |
| Gross profit | -$1.02M | -$643,000 | $2,000 | — | — | — | — | — |
| R&D expense | $1.63M | $1.86M | $1.29M | $1.54M | $1.17M | $2.11M | $1.46M | $1.98M |
| SG&A expense | $1.84M | $3.68M | $3.03M | $2.60M | $2.16M | $1.61M | $1.56M | $1.45M |
| Operating income | -$6.49M | -$6.19M | -$4.32M | -$4.14M | -$3.86M | -$3.72M | -$3.02M | -$3.43M |
| Net income | -$5.84M | -$5.63M | -$3.67M | -$3.46M | -$3.58M | -$3.50M | -$2.60M | -$3.39M |
| EBITDA | -$6.47M | -$6.17M | -$4.31M | -$4.13M | -$3.85M | -$3.71M | -$3.01M | -$3.40M |
| EPS (basic) | -0.09 | -0.08 | -0.05 | — | -0.07 | -0.10 | -0.08 | — |
| EPS (diluted) | -0.09 | -0.08 | -0.05 | — | -0.07 | -0.10 | -0.08 | — |
| Weighted avg. shares (diluted) | 67.16M | 67.16M | 67.16M | — | 48.10M | 36.49M | 31.09M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.29M | $3.15M | $3.66M | $3.91M | $6.70M | $4.08M | $3.22M | $3.11M |
| Short-term investments | $59.54M | $64.22M | $68.84M | $74.68M | $73.45M | $28.59M | $27.17M | $2.36M |
| Receivables | $90,000 | $176,000 | $105,000 | — | — | — | — | — |
| Inventory | $3.21M | $2.91M | $2.26M | $584,000 | — | — | — | — |
| Current assets | $66.87M | $72.17M | $76.53M | $79.82M | $80.78M | $32.89M | $30.66M | $5.82M |
| PP&E, net | $486,000 | $316,000 | $188,000 | $93,000 | $78,000 | $75,000 | $78,000 | $80,000 |
| Total assets | $68.21M | $73.36M | $78.07M | $81.54M | $81.76M | $33.13M | $30.89M | $6.03M |
| Current liabilities | $4.26M | $3.89M | $3.39M | $3.42M | $2.93M | $2.73M | $1.89M | $2.46M |
| Total liabilities | $4.76M | $4.44M | $3.96M | $3.99M | $3.54M | $2.77M | $1.94M | $2.50M |
| Shareholders' equity | $63.45M | $68.93M | $74.11M | $77.55M | $78.22M | $30.36M | $28.95M | $3.53M |
| Shares outstanding | 67.16M | 67.16M | 67.16M | 67.16M | 65.83M | 37.96M | 34.74M | 19.40M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.41M | -$4.99M | -$5.05M | -$3.76M | -$3.84M | -$2.57M | -$2.87M | -$1.69M |
| Capital expenditure | $115,000 | $142,000 | $108,000 | $25,000 | $13,000 | $9,000 | $13,000 | $7,000 |
| Free cash flow | -$5.52M | -$5.13M | -$5.16M | -$3.78M | -$3.85M | -$2.58M | -$2.89M | -$1.70M |
| Investing cash flow | $4.55M | $4.47M | $5.00M | -$1.53M | -$44.71M | -$1.31M | -$24.83M | $1.50M |
| Financing cash flow | $0 | — | — | $2.51M | $51.18M | $4.75M | $27.81M | $2.83M |
| Depreciation & amortization | $28,000 | $15,000 | $12,000 | $10,000 | $10,000 | $12,000 | $15,000 | $26,000 |
| Stock-based compensation | $362,000 | $433,000 | $222,000 | $236,000 | $328,000 | $237,000 | $256,000 | $282,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.